A5074021027- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Peptidase Inhibition and Analysis
- Monoclonal and Polyclonal Antibodies Research
- Ubiquitin and proteasome pathways
- vaccines and immunoinformatics approaches
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Research on Leishmaniasis Studies
Freie Universität Berlin
2022-2024
Humboldt-Universität zu Berlin
2022-2024
Charité - Universitätsmedizin Berlin
2022-2024
Proteasome inhibition is a highly effective treatment for multiple myeloma (MM). However, virtually all patients develop proteasome inhibitor resistance, which associated with poor prognosis. Hyperactive small ubiquitin-like modifier (SUMO) signaling involved in both cancer pathogenesis and progression. A state of increased SUMOylation has been aggressive biology. We found that relapsed/refractory MM characterized by SUMO-high state, high expression the SUMO E1-activating enzyme (SAE1/UBA2)...
Abstract Multiple myeloma (MM) is a plasma cell malignancy of the bone marrow. Despite therapeutic advances, MM remains incurable, and better risk stratification as well new therapies are therefore highly needed. The proteome has not been systematically assessed before holds potential to uncover insight into disease biology improved prognostication in addition genetic transcriptomic studies. Here we provide comprehensive multiomics analysis including deep tandem mass tag-based quantitative...
Not available.